Advertisement
investing

Can This Fallen Biotech Be Revived?

I've been sorely tempted to sell my Gilead shares. But now that they're cheaper, maybe I should buy more.

When I picked up 150 shares of Gilead Sciences (symbol GILD) a little over a year ago, investors were slamming the stock because of concerns about increased competition in the hepatitis-drug market and a decline in the number of patients needing such medications. I figured that the stock was cheap, already reflected all of the bad news and was due for a recovery. I couldn’t have been more wrong.

I wasn’t alone. Bullish analysts had drastically underestimated the depth and speed of the sales slump, and Gilead continued to fall steadily after I invested. It closed at $70 on February 28, down 22% from my purchase price of $90.81 and off a whopping 43% from the record high of $123, set in June 2015.

Advertisement - Article continues below

Because I was getting ready to do my taxes, I started to think that I should dump the stock and claim the loss next year when I file my 2017 return. But just as I was about to sign in to my brokerage account, my phone rang. Then the dogs started pleading to be walked. I began contemplating a new dance class my gym was offering. When it comes to my investments, procrastination may be what I do best.

Advertisement
Advertisement - Article continues below

And that might be a good thing. A few days later, Gilead’s stock had bounced off its recent low, and I was having second thoughts about selling. My decision hinged on the answers to two questions: At the current price, would I invest in Gilead today? And if I did sell, what would I do with the proceeds?

The hepatitis problem. To answer the first question, let’s take a look at Gilead’s business. The biotechnology giant makes drugs to treat hepatitis, HIV, cancer and other illnesses. Two drugs that treat hepatitis C—Sovaldi and Harvoni—have accounted for the bulk of Gilead’s revenues in recent years. But sales of those drugs plunged in 2016, and Gilead said in February that the decline is likely to accelerate in 2017. Why? The drugs actually cure hepatitis C with relatively few side effects. That helps explain Gilead’s explosive sales growth in the first few years following the introduction of Sovaldi in 2013 and Harvoni a year later.

Advertisement - Article continues below

But what’s good for patients has not been good for shareholders. There aren’t enough new hepatitis sufferers to take the place of those who’ve been cured. The reason? Hepatitis C is a virus that was typically spread in hospitals through blood transfusions and organ transplants and often went undetected for decades. Blood banks started screening for this silent killer, as well as for HIV, in the 1990s, dramatically cutting the chance of contracting the diseases via medical procedures. Thus, although more than 3 million people are believed to have hepatitis C, fewer new cases are being reported. As a result, Gilead’s sales, which topped $32 billion in 2015 ($19 billion from Harvoni and Sovaldi), sank to $30 billion in 2016 and could fall to $22 billion this year.

But I’m not giving up. Based on Gilead’s own forecasts, I reckon that, at worst, the firm will earn $5.90 a share in 2017, down from $9.94 in 2016. At today’s price, the shares trade at just 12 times that figure (compared with a price-earnings ratio of 18 for the overall stock market). Earnings easily support the $2.08 per share annual dividend, which gives the stock a generous 3.0% yield. Gilead also has a strong balance sheet, with $32 billion in cash and securities that officials say is earmarked for acquisitions. If Gilead fails to come up with new blockbusters—either by buying them or by creating them in its own labs—sales and profits could fall further in 2018. But the stock is so cheap, I’d still be tempted to buy.

As for the second question—what to do with the proceeds if I sell Gilead—I already have $51,000 sitting in cash in the Practical Portfolio because I’m having trouble finding well-priced stocks. Until I find something better, I’m holding on to my battered Gilead shares.

Advertisement

Most Popular

What Are the Income Tax Brackets for 2020 vs. 2019?
tax brackets

What Are the Income Tax Brackets for 2020 vs. 2019?

The IRS unveiled the 2020 tax brackets, and it's never too early to start planning to minimize your future tax bill.
June 20, 2020
HSAs Get Even Better
Financial Planning

HSAs Get Even Better

Workers have more options with flexible spending accounts, too.
July 2, 2020
17 States That Will Gain or Lose Electoral-College Votes After the 2020 Census
Politics

17 States That Will Gain or Lose Electoral-College Votes After the 2020 Census

Every 10 years, the 435 seats in the House of Representatives are reassigned based on the results of the U.S.
July 2, 2020

Recommended

3 Municipal Bond Funds for Rich, Tax-Friendly Yields
Investing for Income

3 Municipal Bond Funds for Rich, Tax-Friendly Yields

Municipal bond funds allow you to enjoy the benefits of tax-exempt income. By investing CEFs, you can sweeten the pot even further.
July 2, 2020
Kiplinger's Weekly Earnings Calendar
stocks

Kiplinger's Weekly Earnings Calendar

Check out our earnings calendar for the upcoming week, as well as our previews of the more noteworthy reports.
July 2, 2020
Is the Stock Market Closed for the Fourth of July?
Markets

Is the Stock Market Closed for the Fourth of July?

Independence Day falls on a Saturday in 2020. As a result, the bond and stock markets are closed for a long holiday weekend. Here's a look at the mark…
July 2, 2020
17 Wonderful Work-From Home Stocks
stocks

17 Wonderful Work-From Home Stocks

Is the run in work-from-home stocks over? The pros don't think so. These 17 "WFH" stocks appear poised to continue climbing on the longer-term remote-…
July 1, 2020